Rachna Khosla Sells 1,252 Shares of Amgen (NASDAQ:AMGN) Stock

Amgen Inc. (NASDAQ:AMGN) SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Rachna Khosla also recently made the following trade(s):

• On Tuesday, August 11th, Rachna Khosla sold 2,000 shares of Amgen stock. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00.

Amgen Trading Down 0.6%

Shares of AMGN opened at $415.21 on Friday. The stock has a market capitalization of $224.47 billion, a P/E ratio of 25.81, a PEG ratio of 3.88 and a beta of 0.41. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $421.79. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm has a fifty day simple moving average of $370.57 and a two-hundred day simple moving average of $358.93.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, research analysts anticipate that Amgen Inc. will post 22.78 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Friday, August 21st. Amgen’s payout ratio is currently 62.65%.

Institutional Trading of Amgen

Several institutional investors and hedge funds have recently bought and sold shares of AMGN. Polar Asset Management Partners Inc. purchased a new stake in Amgen in the second quarter worth $201,000. Jupiter Topco LLC bought a new position in Amgen in the second quarter worth $323,681,000. American Trust lifted its position in Amgen by 5.5% during the second quarter. American Trust now owns 771 shares of the medical research company’s stock valued at $279,000 after buying an additional 40 shares during the period. PDT Partners LLC bought a new stake in shares of Amgen during the 2nd quarter valued at $2,209,000. Finally, Canada Pension Plan Investment Board boosted its holdings in shares of Amgen by 39.7% during the 2nd quarter. Canada Pension Plan Investment Board now owns 963,209 shares of the medical research company’s stock valued at $348,797,000 after buying an additional 273,719 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on AMGN shares. Sanford C. Bernstein upped their price target on Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research report on Thursday, August 6th. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a research report on Friday, June 12th. Truist Financial boosted their target price on Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Erste Group Bank restated a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Finally, Daiwa Securities Group dropped their price target on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $372.39.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.